Previous 10 | Next 10 |
Marinus Pharmaceuticals (NASDAQ: MRNS ): Q3 GAAP EPS of -$0.26 misses by $0.02 . More news on: Marinus Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Positive Phase 2 IV ganaxolone data in RSE Strong enrollment continues in pivotal CDD study RADNOR, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat ...
RADNOR, Pa., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatri...
RADNOR, Pa., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric dis...
Investment Thesis Backed by positive results from a phase 02 trial for Major Depressive Disorder ((MDD)), the shares of Axsome Therapeutics, Inc. ( AXSM ) have jumped nearly seven times in 2019 so far. Out of the six clinical trials currently in progress, four data readouts will be availab...
Gainers : Precipio (NASDAQ: PRPO ) +68% . Marinus Pharmaceuticals (NASDAQ: MRNS ) +15% . SAExploration Holdings (NASDAQ: SAEX ) +13% . Sonim Technologies (NASDAQ: SONM ) +13% . Aehr Test Systems (NASDAQ: AEHR ) +13% . Contango Oil & Gas Company (NYSEMKT: MCF ) +12% . Sundance Ene...
Marinus Pharmaceuticals (NASDAQ: MRNS ) +39% on positive ganaloxone data . More news on: Marinus Pharmaceuticals, Inc., Pieris Pharmaceuticals, Inc., SAExploration Holdings, Inc., Stocks on the move, Read more ...
Nano cap Marinus Pharmaceuticals (NASDAQ: MRNS ) is up 58% premarket on robust volume in response to positive results from a Phase 2 clinical trial evaluating intravenous ganaxolone in patients with refractory status epilepticus , an emergency situation where the patient has a...
All patients achieved the primary endpoint Target Phase 3 dose identified Preparing for End-of-Phase 2 meeting with FDA Oral platform presentation at Neurocritical Care Society meeting in October Conference call and live webcast to be held today at 8:30 AM ET RADNOR, Pa...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had another lackluster week, opening last Tuesday (September 3) after the long weekend at 3,219.88 points before settling at 3,229.42 points as of 1:32 p.m. EDT on Friday (September 6). Over the short trading week, the US Food and Drug Admin...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...